-
Changes in the new crown oral drug market: the generic version of Pfizer Paxlovid has entered the clinic
Time of Update: 2023-01-05
A search of the "China Clinical Trials Registry" website shows that CSPC registered the bioequivalence trial of nematevir tablets on September 26, 2022According to the trial registration information, the purpose of the trial is to evaluate the nematevir tablets and Pfizer Manufacturing Deutschland produced by Sinopharma Pharmaceutical Group Bioequivalence of the reference preparation nematevir tablets produced by GmbH.
-
Pfizer has become a new generation of multinational "drug king" AstraZeneca's poor performance in the Chinese market
Time of Update: 2022-01-22
The first three quarters of the top 10 multinational pharmaceutical companies were all over US$25 billion, and Novartis, Johnson & Johnson, BMS, GSK, Sanofi, Merck and AstraZeneca ranked fourth to tenth .
-
Pfizer and Johnson & Johnson reach a settlement in the Remicade generic drug lawsuit
Time of Update: 2021-08-05
Pfizer initially filed a lawsuit against Johnson & Johnson in September 2017, claiming that in order to protect the market revenue of its blockbuster drug Remicade, Johnson & Johnson used "exclusive contracts" and other methods that violated the monopoly law to prevent suppliers and patients from using the Remicade generic drug Inflectra.
-
Pfizer and Sanofi "on the list" will the generic drug market be reshuffled?
Time of Update: 2021-04-28
With 17 more varieties, the generic drug market is about to change. Compared with high-priced original research drugs, generic drugs can greatly reduce the burden of patients' medication and the burde
-
EGFR mutation lung cancer first-line treatment of new options! Pfizer's second-generation targeted cancer drug Vizimpro has been approved by the FDA,..
Time of Update: 2021-02-06
OS data from key head-to-head III studies are very encouraging, with the mid-OS in patients treated with Vizimpro's EGFR-activated mutant NSCLC approaching 3 years, a significant improvement over the current clinical first-line treatment, Iressa.
-
New drugs for special dermatitis! Pfizer's next-generation oral JAK1 inhibitor abrocitinib enters the review in the US and Europe!
Time of Update: 2020-11-08
Oct 30, 2020 // -- Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has accepted abrocitinib (100 mg, 200 mg) of new drugs Application (NDA) and granted priority review of the drug, a once-a-day oral JAK1 inhibitor used to treat patients aged ≥12 with moderate to severe endexual dermatitis (AD).
-
A new drug for epidermatitis! Pfizer's next-generation oral JAK1 inhibitor abrocitinib 4 Phase III clinical studies have been successful!
Time of Update: 2020-06-16
June 11, 2020 /PRNewswire/ -- Pfizer has announced that the evaluation of an oral JAK1 inhibitor abrocitinib (PF-04965842) for treatment at an age of 12-18 years and also receiving background external
-
Pfizer announces second-generation EGFR-tyrosine kinase inhibitor target drug Dacutinib (Dozerun ®) officially launched in China
Time of Update: 2020-06-09
lung cancer ranks first in the morbidity and mortality of all types of cancer in China Of these, NSCLC accounts for about 85% of all lung cancer cases In China, EGFR is the most common type of mutat
-
"Challenge" Pfizer! Zhengda Qingjiang's 4 generic drugs are about to be approved
Time of Update: 2020-05-31
ZhengdaQingjiang Ceresibu review timeline Serexibu capsule is the world's first selective nonsteroidal anti-inflammatory analgesics, used to relieve the symptoms and signs of osteoarthritis, relieve
-
Pfizer Lyrica lost 57% market share in three weeks after being blocked by nine generic drugs!
Time of Update: 2019-08-21
Recently, the bionics of Avastin and Herceptin, the Rogowski blockbuster, landed in the United States and was listed as the top drugs in the catalogue by unh health insurance (for details, unh listed
-
[yaocajun] 5-pound bomb detonates the drug circle, Hengrui, hausen, Bayer, Pfizer and Aberdeen; new
Time of Update: 2019-05-13
Highlights: 1 For 12 years, the first long-acting GLP-1 receptor agonist independently innovated in China has been approved; 2 The third domestic PD-1 monoclonal antibody, carrizumab for Hengrui injec
-
GSK is the most eye-catching import drug approved! Novartis and Pfizer actively layout imported generic drugs
Time of Update: 2018-11-05
▍ the third quarter ended According to incomplete statistics, 270 pharmaceutical enterprises had issued the third quarter performance report as of November 1 The total operating revenue was more than
-
Pfizer is betting on 5 bio generic drugs
Time of Update: 2015-11-06
Source: Xinkangjie 2015-11-6 at present, Pfizer is betting on funds from bio generic drug manufacturers The company hopes that its bio generic drugs will cause effects in the U.S market after being li
-
Haizheng Pfizer international production base officially put into production to create high-end generic drugs
Time of Update: 2014-05-29
Mr Xiao Weihong, chief executive officer of Haizheng Pfizer Pharmaceutical Co., Ltd., presented the first box of drugs put into production to the parent company, Haizheng Pfizer Fuyang production base
-
Pfizer will withdraw from the generic drug market without Chinese buyers
Time of Update: 2014-03-04
Source: sina.com 2014-3-4 in the next three years, there will be hundreds of drug patents expired in the world, and at the same time, hundreds of billions of dollars of market space will be released A